Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.53 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.53 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.53 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.53 |
| ▸ | P2RY2 | P41231 | 11/20 | 0.45 |
| ▸ | P2RY6 | Q15077 | 10/20 | 0.44 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.43 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8852266 | 1.00 | SLC28A1 (0.53) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL8852259 | 1.00 | SLC28A1 (0.53) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL13671127 | 0.92 | SLC28A1 (0.58) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL562345 | 0.92 | SLC28A1 (0.58) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL19590359 | 0.91 | SLC28A1 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL17863944 | 0.89 | SLC28A1 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL16906846 | 0.89 | SLC28A1 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL15070792 | 0.89 | SLC28A1 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL16575798 | 0.89 | P2RY2 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL17860663 | 0.88 | SLC28A1 (0.48) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| WO-2023178133-A9 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20180155384-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. | 2018-06-07 | — | — | US | disclosed |
| US-20180155384-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. | 2018-06-07 | — | — | US | disclosed |
| US-9890188-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-9890188-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| WO-2016100569-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| US-20160176910-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. | 2016-06-23 | — | — | US | disclosed |
| US-20160176910-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | SLC28A1 159/4885SLC28A2 603/4885SLC29A1 254/4885 |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | SLC28A1 159/4885SLC28A2 603/4885SLC29A1 254/4885 |
| US-20160176910-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, NT5C2 | SLC28A1 27/4885SLC28A2 31/4885SLC29A1 12/4885 |
| US-20180155384-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, NT5C2 | SLC28A1 27/4885SLC28A2 31/4885SLC29A1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.